samedan logo
 
 
spacer
home > epc > autumn 2007 > ivrs contingency planning
PUBLICATIONS
European Pharmaceutical Contractor

IVRS Contingency Planning

Attempting to anticipate potential problems when running interactive voice response systems is far from straightforward – Samuel Bryant at Averion International Corp reflects on the importance of contingency planning

An interactive voice response system (IVRS) is a phone-based system that allows a user to enter and retrieve data through the guidance of voice prompts for the system. When used in a clinical trial, an IVRS reduces the costs and simplifies the process of patient enrolment and randomisation, drug inventory management, and patient reported outcomes. Therefore, every time the system goes down there is a direct impact on the budget for the sponsor, vendor, or both. Anticipating and avoiding causes for potential problems will help to minimise the amount of downtime a system experiences. Even the most robust systems need to have plans in place for unexpected system failures. Identifying and planning for potential problems ensures that when the unexpected does happen, the resolution is quick and efficient, users of the system have a seamless experience, and the downtime, which equates to cost overrun, is minimised.

ASSIGN AN IVRS RESPONSE TEAM

An IVRS spans across several technologies (including telecommunications, application design and support, database design and support, and server management), so it is not surprising that the IVRS relies on individuals with experience in each corresponding technology. Each member of an IVRS team must be assigned a defined role in supporting the system. This ensures that problem handling and support is provided more efficiently.

Each team member brings their expertise to the system; however, it is not enough for them to stay siloed in their particular role. Cross-training all IVRS team members ensures that the team can continue in the event that some members are not available. A secondary benefit to this cross-training is that it strengthens individual skills (including developmental paths in the company), which results in a robust IVRS development and support team.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Samuel Bryant is the Business Systems and Applications Analyst in the Business Operations Department, at Averion International Corp. He has been involved extensively in IT and business operations at Averion for the last two years, bringing IT solutions to the clinical trial arena by working with various business units to identify areas where technology can improve business processes for the company. He is also responsible for managing the Service Level Agreements with various technology vendors. Samuel has worked in biotech and computer technology for the past 11 years, most recently focusing on application development, management and implementation.
spacer
Samuel Bryant
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLine® ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement